Stock Analysis of Alpha Cognition Inc (ACOG) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ACOG
Close 6.50
Change -0.100 / 1.52 %
Volume 49105.00
Vol Change -45815.00 / 48.27 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Alpha Cognition Inc
PE (TTM)

-4.98

Very Poor
Price / Book

3.34

Very Poor
Price / Sales

13.05

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

141323 K

Enterprise Value

93688.93 K

ROA (TTM)

-49.73

Very Poor
ROE (TTM)

-67.07

Very Poor
Net Margin (TTM)

-262.18

Very Poor
Revenue

%

0
Net Profit

6.28 %

-14636.86 K
Debt to Equity

0.0220

Excellent
Altman Z Score

7.20

Excellent
Quick Ratio

14.81

Excellent
Cash Ratio

14.49

Excellent


Highs/Lows of Alpha Cognition Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week6.254.00 % 1.25 % 6.915.9330-Dec-2526-Dec-25
Two Week5.3521.50 % 1.85 % 6.915.0030-Dec-2518-Dec-25
One Month6.027.97 % 0.052 % 6.914.9930-Dec-2515-Dec-25
Three Month6.510.154 % 2.35 % 7.844.9901-Oct-2515-Dec-25
Six Months9.3330.33 % 10.32 % 11.544.9910-Jul-2515-Dec-25
One year5.8910.36 % 16.39 % 11.543.7510-Jul-2508-Apr-25


Technical View of Alpha Cognition Inc
RSI

58.47

Neutral
MACD

0.083

Strong Bullish
ADX

18.50

Bullish
Super Trend

5.09

Bullish
Williams %R

-21.52

Strong Bearish
CCI

122.82

Mild Bearish


EMA 5

6.36

Bullish
EMA 15

6.06

Strong Bullish
EMA 50

6.26

Strong Bullish
EMA 100

6.79

Mild Bearish
SMA 100

7.09

Mild Bearish
SMA 200

7.48

Strong Bullish
SMA 5 / 20

6.40 / 5.91

Bullish
SMA 15 / 50

5.84 / 6.05

Mild Bearish
SMA 50 / 200

6.05 / 7.48

Strong Bearish




Charts of Alpha Cognition Inc


Returns of Alpha Cognition Inc with Peers
Period / StockACOGACTUSGMOLNSR
1 Week4.00%-6.71%-5.62%-3.16%
1 Mth7.97%-19.79%-8.89%14.24%
3 Mth-0.154%-8.52%-37.63%-5.83%
6mth-30.33%0.164%-22.41%-11.69%
1 Year10.36%-23.12%-58.82%30.09%
2 Year---22.69%231.34%
5 Years---97.31%60.41%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Alpha Cognition Inc with Peers
Ratio / StockACOGACTUSGMOLNSR
PE-4.98-4.52-0.955-3.20
P/B3.3436.305.6127.62
ROA-49.73-228.64-112.22-63.96
ROE-67.07-1392.98-587.710
Debt To Equity0.022000.1890.108
Revenue0
% 		0
% 		57800.00 K
71.30 % 		53494.00 K
26.87 %
Net Income-14636.86 K
6.28 % 		-27285.33 K
10.27 % 		-97941.00 K
60.75 % 		-31404.00 K
118.34 %


Technicals of Alpha Cognition Inc with Peers
Technical / StockACOGACTUSGMOLNSR-
ADX18.5028.1810.4228.48
CMF-0.2630.095-0.216-0.0397
MFI61.7733.9434.4879.51
RSI58.4738.1242.3453.68
MACD Abv SignalTrueFalseFalseFalse
Price Above 50 MATrueFalseFalseTrue-
Price Above 200 MAFalseFalseFalseFalse-


About : Alpha Cognition Inc

Address : 750 West Pender Street, Vancouver, BC, Canada, V6C 2T8
Tel : 604 564 9244
URL : https://www.alphacognition.com
Code : ACOG, ISIN : CA02074J5017, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 12_Nov_2024

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.


Note : All Data Generated at the End of Trading Hours (EOD Data)